Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives - Seite 2
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic
solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly
where conception occurs, is FDA-cleared and has received regulatory approval in Canada. FemBloc permanent birth control in late-stage clinical development is the first and only non-surgical,
in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic
products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house
manufacturing capabilities. Its diagnostic products include FemVue for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath, an intrauterine catheter for
selective fallopian tube evaluation, and FemCerv, an endocervical tissue sampler for cervical cancer diagnosis. For more information visit www.femasys.com, or
follow us on X, Facebook,
and LinkedIn.
Lesen Sie auch
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions,
although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions,
many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current
product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product
candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product
candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our
implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other
reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required
under applicable law.